Dr. Andrew Foy, a cardiologist at Penn State Health, returns to the show to unpack the findings of his JAMA publication exploring industry payments in medicine and their influence on clinical practice. He examines how financial relationships with the industry may shape guideline recommendations, alter quality-of-care metrics, and contribute to potentially inappropriate prescribing practices, particularly in cases of expanded indications. Together, Chadi and Dr. Foy consider critical questions about whether medical societies should face the same scrutiny as individual physicians and whether backlash against industry involvement in healthcare is disproportionate compared to other sectors.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
